AUROPHARMA - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

📈 Swing Trade Analysis for AUROPHARMA

Swing Trade Rating: 4.1

⚙️ Technical Indicators

Current Price: ₹1,158 is slightly above DMA 50 (₹1,145) and below DMA 200 (₹1,185) — suggesting indecision near resistance.

RSI (56.0): Neutral but leaning slightly bullish; indicates neither overbought nor oversold.

MACD (-3.61): Mild bearish divergence, but not strongly negative.

Volume (8.52 lakh) exceeds average weekly volume (7.89 lakh) — implies increased interest/activity.

🔎 Inference: Technically, the stock is consolidating with potential upward movement, especially if it can decisively break above ₹1,185.

💼 Fundamental Factors

Market Cap ₹67,827 Cr.: Large-cap stability with sector strength.

P/E 19.5 vs. Industry P/E 34.0: Undervalued — room for upside.

PEG Ratio (2.40): Slightly high — moderate earnings growth expectations.

ROE (11.2%), ROCE (14.3%): Healthy returns.

EPS ₹59.5 and Book Value ₹557 — decent valuation metrics.

Debt-to-Equity (0.25): Controlled leverage.

PAT Qtr fell from ₹846 Cr to ₹903 Cr: Though it’s up QoQ, Qtr Profit Var -7.19% flags some inconsistency.

🧮 Verdict: Fundamentally sound with valuation edge and stable financial metrics.

✅ Optimal Entry Price

Buy Zone: ₹1,140–₹1,155 — ideally on dips near the 50-DMA.

Stop-Loss: ₹1,120 — previous support zone.

🚪 Exit Strategy (If Already Holding)

Target Exit: ₹1,200–₹1,220 — conservative target near 200-DMA.

Aggressive Exit: ₹1,280–₹1,300 — if it breaks above 200-DMA with volume.

💡 Final Thought

AUROPHARMA is a decent swing trade candidate with balanced technicals and solid fundamentals. It’s not explosive, but if you’re looking for a relatively stable ride with the chance of modest gains, it’s worth keeping on radar — especially if momentum picks up.

Want to dive into more pharma plays or scout stocks with higher swing potential?

Edit in a page